Semaglutide

GLP-1 receptor agonist (Ozempic / Wegovy) — the baseline incretin therapy.

Semaglutide mimics GLP-1, a gut hormone your body releases after eating that tells the brain you're full and slows how fast the stomach empties. Dosed weekly, it dramatically quiets appetite and "food noise," which is what drives the ~15% weight loss — alongside better blood sugar and real cardiovascular benefit. It's the well-established, conservative baseline of the whole class (Ozempic for diabetes, Wegovy for weight). The trade-offs are the GI side effects early on and meaningful muscle loss if you're not lifting and eating enough protein.